Elanco Animal Health, Inc. ELAN

Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026. Jeff Simmons, president and CEO, will participate in a fireside chat on Tuesday, September 22 at 2:10 p.m. BST (9:10 a.m. EDT).

Elanco currently trades at $23.15 per share and has shown little upside over the past six months, posting a small loss of 1.1%. The stock also fell short of the S&P 500’s 14.2% gain during that period.

* Innovation that protects against these pests is driving stronger base business and overall share gains. Pet Health is on track to expectations of high-single digit to low double-digit growth in the second half of 2026.

Elanco Animal Health (ELAN) drew fresh attention after its latest closing price of US$23.17. This put recent share moves and the company’s improving annual revenue and net income figures in sharper focus for investors. Recent moves show mixed momentum for Elanco Animal Health, with a 1-day share price return of 1.36% but a 7-day share price return down 5.43%. However, the 1-year total shareholder return of 24.30% and 3-year total shareholder return of 96.36% point to a much stronger...

Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.

If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.

Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Jeff Simmons, president and CEO, Bob VanHimbergen, executive vice president and CFO, and Bobby Modi, executive vice president U.S. Pet Health and Global Digital Transformation will participate in a fireside chat on Tuesday, September 15 at 2:35 p.m. ET.

The completed 25,000-square-foot Elwood site expansion bolsters 's monoclonal antibody (mAb) production; supports delivery of next-generation pipelineINDIANAPOLIS, IN / ACCESS Newswire / August 31, 2026 / Animal Health Incorporated (NYSE:ELAN) announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens 's leadership in

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

ELWOOD, Kan. (News-Press NOW) — Elanco Animal Health recently completed a $120 million expansion of its Elwood manufacturing facility, quadrupling production capacity at a site that company leaders say will play a central role in developing and producing the next generation of animal health treatments. Company, state and federal officials gathered Wednesday to celebrate completion of the ...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Elanco’s results for the second quarter were positively received by the market, reflecting momentum across both its Pet Health and Farm Animal businesses. Management attributed growth to strong execution in the U.S. and international markets, particularly the success of new products like Zenrelia and Credelio Quattro. CEO Jeffrey Simmons noted that “Zenrelia was the largest contributor to second quarter total Elanco growth,” with broad-based gains from innovative treatments and share gains in co